abstract: OBJECTIVE: To investigate the course of @entity2633 and identify prognostic indicators associated with short- and longterm outcome of @entity158 intensity. METHODS: We prospectively followed @entity1 (n = 349) from 2 randomized controlled trials investigating conservative interventions for @entity2633 in primary care. Uni- and multivariate linear regression analyses were used to investigate the association between potential prognostic indicators and @entity158 intensity (0-100 point scale) measured at 1, 6, and 12 months after randomization. Potential prognostic factors were duration of @entity14228 , @entity4048 , concomitant @entity158 , previous @entity14228 , baseline @entity158 scores, age, gender, involvement of dominant side, social class, and work status. The variables "study" and "treatment" were included as covariates in all models. RESULTS: @entity158 scores at 1 month followup were higher in @entity1 with severe @entity158 , a long duration of @entity14228 , and concomitant @entity158 . At 12 month followup, the only different prognostic indicator for poor outcome was @entity4048 , in place of @entity158 . @entity1 from higher social classes reported lower @entity158 scores at 12 month followup than @entity1 from lower social classes. CONCLUSIONS: @entity2633 seems to be a self-limiting condition in most @entity1 . Long duration of @entity14228 , @entity4048 , and severe @entity158 at presentation are associated with poor outcome at 12 months. Our results will help care providers give @entity1 accurate information regarding their prognosis and assist in medical decision-making.

title: XXXX in general practice: course and prognostic indicators of outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity14228 :: ('MESH:C535618', 'Disease') :: ['elbow complaints']

entities_list: @entity2633 :: ('MESH:D013716', 'Disease') :: ['lateral epicondylitis', 'Lateral epicondylitis']

entities_list: @entity4048 :: ('MESH:D019547', 'Disease') :: ['concomitant neck pain']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain', 'shoulder pain']

answer: @entity2633 :: (MESH:D013716,Disease) :: ['Lateral epicondylitis']


abstract: BACKGROUND: Several randomized controlled trials of cholinesterase inhibitors and @entity3393 in mild to moderate @entity1294 have demonstrated the efficacy of these treatments. However, given these drugs incur considerable cost, the economic argument for their use is less clear. OBJECTIVE: To determine the incremental cost-effectiveness of cholinesterase inhibitors and @entity3393 for mild to moderate @entity1294 . DESIGN: A decision analysis model using a 24-28 week time horizon was developed. Outcomes of cholinesterase inhibitors and @entity3393 and probabilities of adverse events were extracted from a systematic review. Costs of adverse events, medications, and physician visits were obtained from local estimates. Robustness was tested with probabilistic sensitivity analysis using a Monte Carlo simulation. INTERVENTIONS: @entity8124 5 mg daily, @entity8124 10 mg daily, @entity11545 16-24 mg daily, @entity11544 flexible dosing up to 6 mg twice daily, or @entity3393 10 mg twice daily versus standard care. MAIN OUTCOME MEASURES: Incremental cost-effectiveness ratio (ICER) expressed as cost per unit decrease in the @entity195 Assessment Scale-cognitive ( @entity11509 -cog) subscale. RESULTS: @entity8124 10 mg daily was found to be the most cost-effective treatment with an ICER of  400.64 (95%CI,  281.10- 596.35) per unit decline in the @entity11509 -cog subscale. All other treatments were dominated by @entity8124 10 mg, that is, more costly and less effective. CONCLUSION: From a societal perspective, treatment with cholinesterase inhibitors or @entity3393 was more effective but also more costly than standard care for mild to moderate @entity1294 . The @entity8124 10 mg strategy was the most cost-effective and also dominated the other alternatives.

title: Cost-effectiveness: cholinesterase inhibitors and @entity3393 in XXXX .

entities_list: @entity1294 :: ('MESH:D015140', 'Disease') :: ['vascular dementia']

entities_list: @entity11545 :: ('MESH:D005702', 'Chemical') :: ['galantamine']

entities_list: @entity3393 :: ('MESH:D008559', 'Chemical') :: ['memantine']

entities_list: @entity11544 :: ('MESH:C072506', 'Chemical') :: ['rivastigmine']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's Disease"]

entities_list: @entity8124 :: ('MESH:C076946', 'Chemical') :: ['donepezil', 'Donepezil']

answer: @entity1294 :: (MESH:D015140,Disease) :: ['vascular dementia']


abstract: @entity66 has been treated surgically and by various other methods for many years. The most important problem associated with such treatment is recurrence, but cosmetic outcome is another important issue that cannot be ignored. Today, crystallized @entity3971 is recognized as a treatment option associated with good medical and cosmetic outcomes. We hypothesized that the addition of laser depilation to crystallized @entity3971 treatment of @entity66 might increase the rate of success, and this study aimed to determine if the hypothesis was true. @entity1 who were treated with crystallized @entity3971 and 755-nm alexandrite laser depilation were retrospectively analyzed. In total, 42 (31 male and 11 female) @entity1 were treated with crystallized @entity3971 and @entity15890 laser depilation and were followed up between January 2009 and January 2012. In all, 38 @entity1 (90.5%) had @entity102 and 4 (9.5%) had recurrent disease. Among the @entity1 , 26 (61.9%) recovered following 1 crystallized @entity3971 treatment, and the remaining @entity1 had complete remission following repeated treatment. Some @entity1 needed multiple treatments, even up to 8 times. None of the @entity1 had a recurrence during a mean 24 months (range, 6-30 months) of follow-up. Whatever method of treatment is used for @entity66 , hair cleaning positively affects treatment outcome. The present results support the hypothesis that the addition of laser depilation (which provides more permanent and effective depilation than other methods) to crystallized @entity3971 treatment (a non-radical, minimally invasive method associated with very good cosmetic results) can increase the effectiveness of the treatment and also reduce the recurrence rate of the disease.

title: Minimally invasive treatment of XXXX : crystallized @entity3971 and laser depilation.

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Pilonidal disease', 'pilonidal disease']

entities_list: @entity15890 :: ('MESH:C112654', 'Chemical') :: ['alexandrite']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

answer: @entity66 :: (MESH:D004194,Disease) :: ['pilonidal disease']


abstract: PURPOSE: To study the dosimetric predictors of early clinical @entity137 following SBRT in @entity1 with @entity2 and planning target volumes ( @entity343 ) exceeding 80 cm(3). METHODS: Eighteen consecutive @entity1 who were treated using volumetric modulated arc therapy (RapidArc   ) were assessed. All were either unfit or refused to undergo surgery or chemoradiotherapy. @entity343 planning objectives were as used in the ROSEL study protocol. Clinical @entity137 was scored using Common @entity137 Criteria AE4.0. Lung volumes receiving 5, 10, 15, and 20 Gy (V(5), V(10), V(15) and V(20)) and mean lung dose were assessed and correlated to symptomatic @entity1207 ( @entity1207 ). RESULTS: Median age, age-adjusted Charlson-comorbidity score and @entity343 size were 74, 7.5 and 137 cm(3), respectively. At a median follow-up of 12.8 months, 8 deaths were recorded: 5 arising from comorbidity, 2 were potentially treatment-related and 1 had local recurrence. @entity1207 was reported in 5 @entity1 (grade 2 in 3 and grade 3 in 2). All @entity1207 occurred in plans without a high priority optimization objective on contralateral lung. Acute @entity1207 was best predicted by contralateral lung V(5) (p<0.0001). CONCLUSION: After SBRT using RapidArc in @entity2 >80 cm(3), the contralateral lung V(5) best predicts @entity1207 . Limiting contralateral lung V(5) to <26% may reduce acute @entity137 .

title: Treatment of large stage XXXX using stereotactic body radiotherapy (SBRT): planning considerations and early @entity137 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung tumors']

entities_list: @entity1207 :: ('MESH:D017564', 'Disease') :: ['radiation pneumonitis', 'RP']

answer: @entity2 :: (MESH:D008175,Disease) :: ['I-II lung tumors']


abstract: BACKGROUND _ AIMS: To investigate the effect on dietary intake of the PRo-active Interdisciplinary Self-MAnagement (PRISMA) program, developed analogous to DESMOND, in overweight type 2 @entity6 @entity1 . METHODS: All type 2 @entity6 @entity1 referred to the @entity6 Outpatient Clinic of the VU University Medical Center Amsterdam with a BMI >25kg/m(2), were eligible for inclusion to the PRISMA program. At baseline and after 3, 6 and 12 months of follow-up, macronutrient intake, anthropometric, biomedical and psychosocial measures were evaluated by using Generalized Estimation Equations. RESULTS: Included into the study were 38 @entity1 , of which 22 completed a 1-year follow-up. After 6 months energy and macronutrient intake were significantly decreased. Reductions after 12 months were still significant for protein, unsaturated fat and dietary fiber and borderline significant for energy and saturated fat intake. @entity1 positively evaluated the program, and most @entity1 held the view that they had learned something from @entity32880 . CONCLUSIONS: The PRISMA program reduced energy and macronutrient intake up to 6 months. After 6 months, attention should be paid to @entity1 ' food product choices. Follow-up counselling might further improve long-term outcome. This pilot study shows that the PRISMA program is promising in decreasing dietary intake in newly diagnosed and established overweight type 2 @entity6 @entity1 in secondary care.

title: Effects of the PRo-active Interdisciplinary Self-MAnagement (PRISMA, Dutch DESMOND) program on dietary intake in type 2 XXXX outpatients: a pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: The aim of this study was to review published reports on the feasability, results, and reliability of sentinel node biopsy in cases of ipsilateral recurrent @entity0 . A Medline search on publications from January 1999 to December 2007 and cross-references in published articles were looked for. We identified 16 reports on sentinel node biopsy in recurrent @entity0 , including a total of 287 @entity1 . In 210/287 (73.2%) a sentinel node was identified, 77/210 (37.7%) had had previous axillary lymph node dissection and 131 (62.3%) a previous sentinel node procedure. Aberrant lymphatic @entity717 was noted in 68/210 (32.4%). Of these 16/68 (23.6%) were located in the @entity717 . Of the removed contralateral axillary sentinel nodes 8/17 (47.1%) were invaded by @entity5 . We conclude that sentinel node biopsy in cases of recurrent ipsilateral @entity0 is feasible. In about one out of three cases @entity717 with invasion in almost half the cases takes place. The therapeutical consequences of these findings need further study.

title: Sentinel node biopsy for ipsilateral XXXX recurrence: a review.

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['drainage to the contralateral axilla', 'drainage, other than the ipsilateral axilla', 'contralateral axilla']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: Endosonography (ES) was used for the preoperative @entity2802 (1987) staging of @entity5 in 43 @entity1 with @entity788 and 24 @entity1 with @entity189 . These results were correlated with the histologic findings of resected specimens. Early-stage @entity5 could be distinguished from advanced stages of @entity5 with ES. Detailed images of ductular and parenchymal abnormalities allowed distinction between @entity3123 based on anatomic location. The overall accuracy of ES in the assessment of @entity5 classification in @entity3123 was 92% and 88%, respectively. In diagnosing regional lymph nodes in @entity788 the accuracy of ES was 74% and 54%, respectively. For diagnosing metastatic lymph nodes in @entity3123 the accuracy of ES was 91% and 80%, respectively. The prevalence of lymph node metastases in T1 @entity5 was 40% and 0%, respectively. Discrimination between inflammation and metastases was difficult with ES. ES was not accurate in assessing distant metastases because of the limited penetration depth of ultrasound.

title: XXXX : preoperative @entity2802 classification with endosonography.

entities_list: @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic and ampullary carcinomas', 'pancreatic and ampullary carcinoma']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic and ampullary tumors', 'pancreatic cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'pancreatic cancers and T1 ampullary carcinomas', 'cancer', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['ampullary carcinomas']

answer: @entity189 :: (MESH:D002277,Disease) :: ['Ampullopancreatic carcinoma']


abstract: To facilitate the diagnosis of @entity2338 and monitor GH therapy, we constructed two reference models to allow comparison of serum IGF binding protein (IGFBP)-3 concentrations and @entity442 to @entity2301 ratios among @entity1 throughout childhood and adolescence. This report presents equations for determining the sd score of @entity2301 and @entity442 to @entity2301 measurements for individual @entity1 . The data set contains serum values from 468 healthy @entity1 and adolescents (232 males, 236 females; ages 1.1-18.3 yr) whose height, weight, and body mass index were within +/- 3 sd of means. Puberty was classified according to breast development (B) and testicular volume into pre-, early, mid-, and late puberty. The values of @entity2301 and @entity442 to @entity2301 ratios were log transformed, and multiple linear regression analysis was used to identify models for converting serum concentrations into sd scores. The models include the variables of age, gender, and puberty and take into account the interactions among these variables. The best linear models explain 42% of the variation in serum @entity2301 concentrations and 50% of the variation in serum @entity442 to @entity2301 concentrations. The relationship between age and log( @entity2301 ) was positive for @entity1 in pre-, early, and midpuberty. In late puberty, values were higher than earlier in puberty, and there was a negative relationship with age. For @entity1 the relationship between age and log( @entity2301 ) also was positive in pre- and early puberty, with larger effect for @entity1 older than 8 yr. Values for @entity1 in midpuberty were relatively constant, and in late puberty values were higher than earlier in puberty, and there was a negative relationship with age. The relationship between age and log( @entity442 to @entity2301 ratio) was positive for @entity1 in pre-, early, and early midpuberty (volume = 9-14 ml). In late midpuberty (volume = 15-19 ml), the relationship between age and @entity442 to @entity2301 ratio was negative. In late puberty, values were relatively constant and higher than earlier in puberty. For @entity1 in prepuberty, the relationship with age was positive, with a larger effect in @entity1 older than 8 yr. In early puberty, the @entity1 ' values were relatively constant. In early midpuberty (B = 3), log( @entity442 to @entity2301 ratio) values were higher for @entity1 than @entity1 of the same age. In late midpuberty (B = 4), the relationship with age was negative, and in late puberty values were relatively constant and higher than earlier in puberty.

title: Reference values for XXXX ( @entity2301 ) and the ratio of insulin-like growth factor-I to @entity2301 throughout childhood and adolescence.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'girls', 'boys']

entities_list: @entity2338 :: ('MESH:D004393', 'Disease') :: ['GH deficiency']

answer: @entity2301 :: (3486,Gene) :: ['insulin-like growth factor-binding protein-3']


abstract: @entity455 is a hallmark associated with disease onset in @entity7643 and @entity7643 . In addition to direct viral damage, immune responses to @entity778 may also underlie the pathogenesis of disease. We have proposed a mechanism of molecular mimicry in which Abs directed against DV nonstructural protein 1 ( @entity8768 ) cross-react with endothelial cells and induce damage. In this study, we demonstrated the inflammatory endothelial cell activation induced by anti-DV @entity8768 via the transcription factor NF-kappaB-regulated pathway. Protein phosphorylation and NF-kappaB activation were observed after anti-DV @entity8768 stimulation in a @entity1 microvascular endothelial cell line-1. The cytokine and chemokine production, including @entity650 , @entity687 , and @entity2842 , but not @entity5737 , in endothelial cells increased after treatment with anti-DV @entity8768 Abs. The expression of @entity650 , @entity687 , and @entity2842 was blocked by the preabsorption of anti-DV @entity8768 with DV @entity8768 or by the inhibition of NF-kappaB activation. Furthermore, the increases in both @entity2071 expression and the ability of @entity1 PBMC to adhere to endothelial cells were also observed, and these effects were inhibited by pretreatment with anti- @entity2071 or anti- @entity2842 Abs. Therefore, in addition to endothelial cell apoptosis, as previously reported, inflammatory activation occurs in endothelial cells after stimulation by anti-DV @entity8768 Abs. These results suggest the involvement of anti-DV @entity8768 Abs in the vasculopathy of @entity778 .

title: Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against XXXX .

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['DV infection', 'dengue virus (DV) infection']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['Vascular dysfunction']

entities_list: @entity7643 :: ('MESH:D019595', 'Disease') :: ['dengue hemorrhagic fever', 'dengue shock syndrome']

answer: @entity778 :: (MESH:D015658,Disease) :: ['dengue virus nonstructural protein 1']


abstract: Curative radiotherapy, with or without concurrent chemotherapy, is recognized as a standard treatment option for muscle-invasive @entity150 . It is commonly used for two distinct groups of @entity1 : either for those medically unfit for surgery, or as part of a 'bladder preserving' management plan incorporating the possibility of salvage cystectomy. However, in both situations, the approach to radiotherapy varies widely around the world. The Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group recognised a need to develop consistent, evidence-based guidelines for @entity1 selection and radiotherapy technique in the delivery of curative radiotherapy. Following a workshop convened in May 2009, a working party collated opinions and conducted a wide literature appraisal linking each recommendation with the best available evidence. This process was subject to ongoing re-presentation to the Faculty of Radiation Oncology Genito-Urinary Group members prior to final endorsement. These Guidelines include @entity1 selection, radiation target delineation, dose and fractionation schedules, normal tissue constraints and investigational techniques. Particular emphasis is given to the rationale for the target volumes described. These Guidelines provide a consensus-based framework for the delivery of curative radiotherapy for muscle-invasive @entity150 . Widespread input from radiation oncologists treating @entity150 ensures that these techniques are feasible in practice. We recommend these Guidelines be adopted widely in order to encourage a uniformly high standard of radiotherapy in this setting, and to allow for better comparison of outcomes.

title: Australian _ New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

answer: @entity150 :: (MESH:D001749,Disease) :: ['urothelial carcinoma of the bladder']


abstract: PURPOSE: The instrument crowding derived from commercially available access devices in @entity302 ( @entity302 ) is a challenge to overcome. This study was designed to evaluate the short-term surgical outcomes of @entity302 by applying a self-made device in @entity1 with benign @entity1049 . @entity1 AND METHODS: We collected and reviewed the medical records of @entity1 who received SILC by using a self-made glove-port system from March 2007 to July 2012. All operations were performed by a single surgeon. Sixty-four @entity1 (36 males and 28 females) were enrolled for this study. Among them, 15 @entity1 received right-side colon resection, 31 @entity1 received left-side colon resection, and 18 @entity1 received total colectomy. RESULTS: In the analysis of medical records from these groups of @entity1 , we found that there was no significant difference of gender, body mass index, @entity5 size, incision length, and @entity190 among these three groups. Furthermore, no significant difference of the @entity158 scores, average length of hospital stay, and average duration of bowel return was observed among these three groups. However, it was notable that younger age, longer duration of operation, and longer bowel resection were indeed significantly found in the @entity1 undergoing total colectomy. On the other hand, curved instruments were used in 5 (16.1%) of 31 @entity1 with left-side colon resection. CONCLUSIONS: A simple self-made glove-port device was proven as a practical method of @entity302 for @entity14 . These findings suggested that single-incision laparoscopic total colectomy provides compatible clinical outcome in the @entity1 with benign @entity1049 compared with the other two surgical procedures used in this study.

title: Single-incision laparoscopic colectomy using self-made glove port for benign XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['single-incision laparoscopic surgery', 'SILS']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal diseases']

entities_list: @entity1049 :: ('MESH:D003108', 'Disease') :: ['colon diseases']

answer: @entity1049 :: (MESH:D003108,Disease) :: ['colon diseases']


abstract: BACKGROUND: @entity354 ( @entity354 ) and @entity453 commonly co-exist. @entity453 @entity1 may mistake @entity354 -induced @entity158 for @entity158 or @entity354 might @entity951 . AIM: To investigate if @entity354 might contribute to nocturnal/rest @entity662 among @entity453 @entity1 . METHODS: Double-blind placebo-controlled crossover study investigating effect of @entity10042 on @entity662 ; 125 @entity1 with angiographically proven @entity453 enrolled with at least one weekly episode of @entity158 , randomized to @entity10042 30 mg daily or placebo with crossover after 4 weeks. Symptoms recorded and QOL assessed by Nottingham Health Profile Questionnaire; ST segment @entity308 episodes counted from 24 h electrocardiographic monitoring in final week of both periods. STATISTICAL ANALYSIS: ANCOVA with period and carryover analysis. RESULTS: In all, 108 @entity1 completed the study. There was a modest increase in @entity158 -free days on @entity10042 vs. placebo (P < 0.02), with fewer days with @entity158 at rest (P < 0.05) and at night (P < 0.009) on @entity10042 vs. placebo, but no significant differences in ST segment @entity308 episodes (P = 0.64). There was a trend for reduction in the 'physical @entity158 ' QOL domain. CONCLUSIONS: Among @entity453 @entity1 , @entity10042 modestly increases @entity158 . As @entity10042 did not affect ST segments, this may be by suppression of @entity354 -provoked @entity158 misinterpreted as angina, rather than acid-provoked ischaemia.

title: Clinical trial: @entity662 caused by presumed @entity354 in @entity453 - controlled study of XXXX vs. placebo.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['provoke angina']

entities_list: @entity10042 :: ('MESH:C058687', 'Chemical') :: ['lansoprazole']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain-free days and reduces rest/nocturnal pain', 'pain', 'nocturnal/rest pain', 'cardiac pain']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['GER', 'Gastro-oesophageal reflux']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['Coronary artery disease', 'coronary artery disease']

answer: @entity10042 :: (MESH:C058687,Chemical) :: ['lansoprazole']


abstract: CONTEXT: Several studies have indicated that atypical antipsychotics (AAP) induce @entity3119 . Research exploring the mechanism of this phenomenon, however, has been extremely limited. Considering the indirect evidence of genetic control and difficulties in developing animal models and performing gene expression studies, genetic association studies could be an important approach to understanding the molecular mechanism of AAP-induced OC symptoms. The @entity2227 transporter gene @entity17383 , which was recently reported to be associated with @entity3119 ( @entity3119 ), is a promising candidate gene for susceptibility to AAP-induced OC symptoms. OBJECTIVE: To determine whether polymorphisms in @entity17383 are associated with @entity1444 -induced OC symptoms in @entity1 with @entity161 . DESIGN: A pharmacogenetic case-control association study. SETTING: Outpatient @entity161 clinics. @entity1 : Clinically stable @entity1 with @entity161 who were receiving AAP treatment (n = 94; OC group). The OC group consisted of 40 @entity1 with AAP-induced OC symptoms, and the non-OC group consisted of 54 @entity1 who had received AAP for more than 24 months without developing OC symptoms. MAIN OUTCOME MEASURES: Allele, genotype, and haplotype frequencies. The association was tested with a logistic regression model using age, sex, and medication type as covariates. RESULTS: Trends of association were observed in @entity31439 and @entity31440 (nominal P = .01; adjusted permutation P = .07) for the dominant model that was the inheritance model that best fit our data. In the haplotype -based analysis, the A/C/G haplotype at @entity31439 - @entity31441 - @entity31440 showed a significant association with AAP-induced OC symptoms; this association withstood multiple test correction (nominal P = .01; adjusted permutation P = .04; odds ratio, 3.955; 95% confidence interval, 1.366-11.452, for dominant model). CONCLUSIONS: These results suggest that sequence variations in @entity17383 are associated with susceptibility to AAP-induced OC symptoms. This is the first published pharmacogenetic study on this phenomenon and provides preliminary evidence of the involvement of glutamatergic neurotransmission in the pathogenesis of AAP-induced OC symptoms.

title: Association of the @entity2227 transporter gene XXXX with atypical antipsychotics-induced @entity3119 .

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity3119 :: ('MESH:D009771', 'Disease') :: ['obsessive-compulsive disorder', 'obsessive-compulsive (OC) symptoms', 'OCD']

answer: @entity17383 :: (6505,Gene) :: ['SLC1A1']


abstract: Mesenchymal stem cells (MSCs) represent a new tool for delivery of therapeutic agents to @entity5 . The cytokine interleukin-12 (IL-12) has demonstrated a potent anti- @entity5 activity in a variety of @entity19 @entity5 models. In this study, @entity1 MSCs were isolated from @entity1 bone marrow and identified by phenotype analysis and differentiation assays. The anti- @entity5 activity of @entity1 MSCs stably transduced with a recombinant adenoviral vector expressing the @entity19 IL-12 (MSC/IL-12) were evaluated in a @entity19 xenograft model of @entity1358 ( @entity1358 ). Expression and bioactivity of the transgenic protein IL-12 from adenoviral vector were confirmed prior to in vivo studies. A nude @entity19 model of @entity1358 was developed by subcutaneously injection of 786-0 cells into @entity19 . MSC/IL-12 was injected into the lateral tail vein with single dose. Results indicated that systemic administration of MSC/IL-12 reduced the growth of 786-0 @entity1358 and significantly prolonged @entity19 survival. These transfected cells could home to @entity5 after intravenous injection and largely produce local IL-12 protein. In contrast, systemic level of IL-12 was modestly elevated. Further studies showed that the anti- @entity5 activity of the MSC/IL-12 was dependent on the presence of natural killer (NK) cells and @entity60 in this experimental setting. These data demonstrate the potential of adult MSC constitutively producing IL-12 to reduce the growth of @entity1358 and enhance the @entity5 -bearing @entity19 survival.

title: Therapeutic potential of XXXX mesenchymal stem cells producing IL-12 in a @entity19 xenograft model of @entity1358 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors']

entities_list: @entity19 :: ('10090', 'Species') :: ['mouse', 'nude mice', 'murine']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: CONTEXT: Soluble @entity6459 (sEng), a coreceptor for TGF with antiangiogenic properties, acts synergistically with soluble fms-like @entity669 kinase 1 (sFlt1) to induce symptoms of @entity2102 ( @entity2142 , elevated liver enzymes, low platelets) syndrome in animal models and to promote a preeclamptic phenotype. Pregnant @entity1 with @entity1468 show increased sEng concentrations in circulation, whereas the sEng increase is detectable months before the clinical onset of the disease. OBJECTIVE: The aim of the study was to determine whether maternal sEng is altered in pregnancies with normotensive @entity1592 ( @entity1592 ). DESIGN: sEng and sFlt1 were retrospectively determined by a commercial ELISA. @entity1 : The study included 11 normotensive pregnancies with @entity1592 , 18 pregnancies with @entity1468 , and 15 gestational-age-matched controls. RESULTS: @entity1 with @entity1468 showed significantly higher sEng concentrations compared with controls (57.0 ng/ml vs. 5.3 ng/ml; P < 0.001). Also @entity1592 pregnancies showed significantly elevated sEng concentrations (25.9 ng/ml; P < 0.001), but the levels were lower compared with the preeclamptic @entity1 . There was a strong positive correlation between the sEng and sFlt1 concentration (Pearson 0.552; P < 0.01). Similar to sEng, the maternal sFlt1 concentration is highest in the preeclamptic @entity1 (8388 vs. 2602 pg/ml; P < 0.01) but also significantly elevated in the @entity1592 @entity1 (6952 pg/ml; P < 0.01). CONCLUSIONS: Pregnancy with @entity1592 , but without maternal symptoms, was characterized by elevated sEng concentrations in circulation. Although this finding is less pronounced when compared with @entity1468 , sEng seems to be involved in different clinical manifestations of placental pathology.

title: Maternal plasma concentrations of soluble @entity6459 in pregnancies with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'PATIENTS']

entities_list: @entity1592 :: ('MESH:D005317', 'Disease') :: ['IUGR', 'intrauterine growth restriction']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['manifest preeclampsia', 'preeclampsia']

entities_list: @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity1592 :: (MESH:D005317,Disease) :: ['intrauterine growth restriction']


abstract: PURPOSE: Umbilical and @entity547 repairs are minor, but are commonly conducted surgical procedures. Long-term results have only been sparsely investigated. Our objective was to investigate the risk of chronic complaints after a simple sutured repair for small umbilical and @entity547 . METHODS: A retrospective cohort study with a 5-year questionnaire and clinical follow-up was conducted. @entity1 undergoing primary elective, open non-mesh umbilical or epigastric sutured hernia repair were included. @entity1 completed a structured questionnaire regarding chronic complaints during work and leisure activities using a verbal rating scale. The primary outcome was chronic complaints. RESULTS: A total of 295 @entity1 were included for analysis after a median of 5.0-year (range 2.8-8.0) follow-up period. Follow-up results were achieved from 262 of the included @entity1 (90  % response rate). Up till 5.8  % of the @entity1 reported moderate or severe @entity158 and discomfort. Work and leisure activities were restricted in 8.5 and 10.0  % of @entity1 , respectively. @entity1 with chronic complaints had a higher incidence of recurrence (clinical and reoperation), than @entity1 with none or mild complaints (78.6 vs. 22.2  % (P   <   0.001)). The recurrence rate was significantly higher after a repair with absorbable suture (20.1  %) compared with non-absorbable suture repair (4.2  %) (P   <   0.001). CONCLUSION: We found that chronic complaints after a simple sutured umbilical or epigastric repair was in the level of 5.5  % and could in part be explained by recurrence. Furthermore, absorbable suture should be omitted to reduce risk of recurrence.

title: Chronic complaints after simple sutured repair for umbilical or XXXX may be related to recurrence.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity547 :: ('MESH:D006547', 'Disease') :: ['epigastric hernia', 'epigastric hernias']

answer: @entity547 :: (MESH:D006547,Disease) :: ['epigastric hernias']


abstract: BACKGROUND: Hepatectomy can be performed with a low mortality rate, but massive @entity548 during the operation remains a potentially lethal problem. The Pringle maneuver is traditionally used during hepatectomy to reduce @entity190 , but the effect on the metabolic function of hepatocytes is potentially harmful. Although our randomized study showed that an intermittent Pringle maneuver is safe and effective during hepatectomy, the upper limit of the duration of the Pringle maneuver is not known. HYPOTHESIS: The liver can tolerate intermittent Pringle maneuver if the duration is not excessive. DESIGN: From July 20, 1995, to November 25, 1997, 112 @entity1 underwent hepatectomy for @entity96 . The data of 50 @entity1 who had hepatectomy without the Pringle maneuver were compared with those of 62 @entity1 who had a liver transection using a Pringle maneuver for 20 minutes and a 5-minute clamp-free interval. The data were collected prospectively. MAIN OUTCOME MEASURES: The surface area of liver transection was measured, and @entity190 during liver transection per centimeter square of transection area was calculated. Routine liver biochemical tests, arterial @entity6178 body ratio (AKBR), and plasma cytokine-interleukin (IL) 1alpha, 1beta, 2, and 6, and @entity5 necrosis factor alpha--levels were measured before and after the operation. The morbidity and hospital mortality rates were also compared among the @entity1 with different @entity63 durations and those without an intermittent Pringle maneuver. SETTING: Tertiary referral center. RESULTS: The cutoff point of accumulated @entity63 time that induced substantial @entity409 , as shown by the postoperative recovery rate of the AKBR, was found to be 120 minutes. Compared with the control group, the @entity1 whose accumulated @entity63 time was shorter than 120 minutes had less @entity190 related to transection area (10 mL/cm2 vs 22 mL/cm2; P<.001), less blood transfused (0 L vs 0.6 L; P = .004), a shorter transection time related to transection area (2.0 min/cm2 vs 2.8 min/ cm2; P = .002), a significantly higher AKBR in the first 2 hours after liver transection, an equal recovery rate of the AKBR, and a comparable increase of the plasma level of @entity650 postoperatively. For the @entity1 whose accumulated @entity63 time was longer than 120 minutes, @entity190 from the transection area was less than for the control group (14 mL/cm2 vs 22 mL/cm2; P<.05), but the transection time related to the transection area and the blood transfusion volume did not differ from those of the control group. Furthermore, they had a significantly lower recovery rate of the AKBR and higher plasma levels of @entity650 postoperatively than the control group.

title: Tolerance of the liver to intermittent pringle maneuver in hepatectomy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumors']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver damage']

answer: @entity96 :: (MESH:D008113,Disease) :: ['liver tumors']


abstract: PURPOSE: To determine current clinical predictors and visual outcomes of @entity1 who undergo pars plana vitrectomy ( @entity2286 ) for retained lens material. DESIGN: Retrospective, noncomparative, consecutive case series. METHODS: Medical records of 166 @entity1 with complicated @entity231 surgery who underwent @entity2286 for retained lens material at Retina Vitreous Consultants of Pittsburgh between January 1, 2001 and January 1, 2007 were reviewed. Main outcome measures include final @entity227 , development of @entity726 , @entity1713 , and @entity1103 . RESULTS: At the final examination, 120 @entity1 (72.3%) had a visual outcome of 20/40 or better and 18 @entity1 (10.8%) had a visual outcome of 20/200 or worse. In @entity1 without any preoperative eye conditions, 82.6% achieved a final vision of 20/40 or better. Multivariable analysis showed that predictors for visual outcomes of 20/40 or better were better presenting vision (P = .001), insertion of a posterior chamber lens (P = .005), and absence of preoperative @entity2194 (P = .001). Predictors for visual outcomes of 20/200 or worse were the absence of an anterior vitrectomy at @entity231 surgery (P = .005), absence of a sulcus lens (P = .011), presence of preexisting @entity2194 (P = .02), and development of @entity726 (P = .001). Performing a @entity2286 within 7 days of @entity231 surgery was associated with a lower risk of developing @entity726 (P = .005). CONCLUSIONS: Current techniques for management of retained lens material may contribute to improved visual outcomes based on our series. We recommend that the @entity231 surgeon perform an anterior vitrectomy, place a posterior chamber lens if possible, and consult a retina specialist for a @entity2286 within 7 days to decrease the risk of developing @entity726 .

title: Clinical predictors and outcomes of pars plana vitrectomy for retained lens material after XXXX extraction.

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual acuity']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['eye disease']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachments']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma', 'secondary glaucoma']

entities_list: @entity1103 :: ('MESH:D008269', 'Disease') :: ['cystoid macular edema']

answer: @entity231 :: (MESH:D002386,Disease) :: ['cataract']


abstract: BACKGROUND: The purpose of this study was to investigate the impact of histology on survival stratified by the Graded Prognostic Assessment (GPA) for @entity1149 ( @entity1149 ) in a group of selected @entity1 treated recently. METHODS: A total of 171 @entity1149 @entity1 with brain metastases treated by hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy between 2001 and 2011 were included. The GPA score was calculated for each @entity1 . @entity5 histologies were categorized into @entity420 ( @entity420 ) and non- @entity420 . @entity1349 ( @entity1349 , in months) was calculated using the Kaplan-Meier method. The log-rank test was used to determine statistical differences. RESULTS: MSTs by histology were: @entity420 15 (n = 92) and non- @entity420 10 (n = 79) (p < 0.001). For all @entity1 , the MSTs by GPA score were: GPA 3.5-4, 24; GPA 2.5-3, 15; GPA 1.5-2, 9 and GPA 0-1, 6 (p < 0.001). The histology of @entity420 showed a statistically significant higher @entity1349 than non- @entity420 for @entity1 with GPA 2.5-4. For GPA 2.5-3, MSTs were: @entity420 18, non- @entity420 10 (p = 0.007); for GPA 3.5-4, MSTs were: @entity420 30, non- @entity420 17 (p = 0.046). For GPA 0-2, MSTs did not differ significantly by histology. For GPA 0-1, MSTs were: @entity420 8, non- @entity420 4 (p = 0.146); GPA 1.5-2, MSTs were: @entity420 10, non- @entity420 8 (p = 0.291). We further found that non- @entity420 in upper GPA class (3.5-4) had similar survival with @entity420 in lower GPA class (2.5-3) (MSTs were 17 and 18, respectively, p = 0.775). This phenomenon also happened between @entity1 of non- @entity420 in upper GPA class (2.5-3) and those of @entity420 in lower GPA class (1.5-2) (MSTs were both 10, p = 0.724). CONCLUSIONS: We confirmed that the histology of @entity1149 had effect on the GPA in these selected @entity1 treated recently. @entity420 showed a statistically significant higher @entity1349 than non- @entity420 with GPA 2.5-4. The non- @entity420 in upper GPA classes (3.5-4 and 2.5-3) had similar survival to @entity420 in lower GPA classes (2.5-3 and 1.5-2, respectively). The histology as a new factor should be added to the original GPA for @entity1149 .

title: The effect of XXXX histology on survival as measured by the graded prognostic assessment in @entity1 with brain metastases treated by hypofractionated stereotactic radiotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['ADCA', 'adenocarcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['Median survival time', 'MST']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: Cosmetics Europe, The Personal Care Association, known as Colipa before 2012, conducted a program of technology transfer and assessment of Within/Between Laboratory (WLV/ @entity26240 ) reproducibility of the SkinEthic    Reconstituted @entity1 Corneal Epithelium (HCE) as one of two @entity1 reconstructed tissue eye @entity146 test methods. The SkinEthic    HCE test method involves two exposure time treatment procedures - one for short time exposure (10 min - SE) and the other for long time exposure (60 min - LE) of tissues to test substance. This paper describes pre-validation studies of the SkinEthic    HCE test method (SE and LE protocols) as well as the Eye Peptide Reactivity Assay (EPRA). In the SE WLV study, 30 substances were evaluated. A consistent outcome with respect to viability measurement across all runs was observed with all substances showing an SD of less than 18%. In the LE WLV study, 44 out of 45 substances were consistently classified. These data demonstrated a high level of reproducibility within laboratory for both the SE and LE treatment procedures. For the LE @entity26240 , 19 out of 20 substances were consistently classified between the three laboratories, again demonstrating a high level of reproducibility between laboratories. The results for EPRA WLV and @entity26240 studies demonstrated that all substances analysed were categorised similarly and that the method is reproducible. The SkinEthic    HCE test method entered into the experimental phase of a formal ECVAM validation program in 2010.

title: Cosmetics Europe multi-laboratory pre-validation of the SkinEthic    reconstituted XXXX corneal epithelium test method for the prediction of eye @entity146 .

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritation']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: A @entity1 @entity2 -associated antigen was purified from a saline extract of a @entity2220 . The antigen was demonstrated in extracts of @entity2220 . The antigen was demonstrated in extracts of @entity2 with the use of an absorbed antiserum by double-diffusion immunoprecipitation. The antiserum did not react with extracts of normal lung or other normal tissues, and the antigen was immunologically distinct from other @entity5 -associated antigens. Purification was achieved by antibody affinity chromatography and preparative @entity2975 gel electrophoresis. Isolation procedures were monitored by immunoreactivity with absorbed monospecific antiserum. The antigen was labeled with 125I and judged homogeneous by 1) @entity2975 gel elecrophoresis in detergent and nondetergent gels, 2) molecular sieve chromatography, 3) ion exchange chromatography, and 4) sucrose gradient sedimentation analysis. A molecular weight of 77,000 was calculated from the s20.w value of 4.24S and from the D20.w value of 5.0X10(-7) cm2/sec. @entity3208 gel electrophoresis indicated a subunit molecular weight of 42,000. The Stokes radius of the antigen was 40 A and the frictional ratio was 1.42, indicating a nonspherical molecule. The purified radioiodinated antigen could be quantitatively precipitated with specific antiserum.

title: Purification and characterization of a XXXX @entity2 -associated antigen.

entities_list: @entity3208 :: ('MESH:D012967', 'Chemical') :: ['Sodium dodecyl sulfate']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung tumors', 'lung tumor']

entities_list: @entity2975 :: ('CHEBI:51135', 'Chemical') :: ['polyacrylamide']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: The aim of this study was to report on 15-year long-term results of a randomized controlled trial comparing extended drainage procedure (Frey) and classical resectional procedure [pylorus-preserving pancreatoduodenectomy (PD)] in @entity1 with chronic @entity788 . BACKGROUND: @entity1689 is a common @entity32 with a prevalence of 10 to 30 cases per 100,000 inhabitants. It is characterized by the progressive conversion of pancreatic parenchyma to fibrous tissue. Different surgical procedures are used in treatment of persistent @entity158 . METHODS: Sixty-four @entity1 suffering from chronic @entity788 with inflammatory mass in the pancreatic head were randomly assigned in 2 treatment groups (PD, n = 32) and (Frey, n = 32). The perioperative course of the randomized controlled trial and the 7 years follow-up have been previously published. All participating @entity1 were contacted with a standardized, validated questionnaire (EORTC QLQ C30) to evaluate the long-term survival, quality-of-life @entity158 , and exocrine and endocrine function. RESULTS: In the 15-year long-term follow-up, the @entity158 control was good and comparable between both groups, but the quality of life was better after Frey procedure in regard of the physical status [PD: 100 (0-100) vs PD: 60 (0-100) (P = 0.011)]. No significant differences in terms of the @entity158 Score were detected between both groups [PD: 7 (0-100) vs Frey 4 (0-100) P = 0.258]. Seven @entity1 after Frey OP and 6 @entity1 after PD were free of @entity158 . Analyzing the postoperative overall survival, a higher long-term mortality was found after PD (53%) than that found after Frey procedure (30%) resulting in a longer mean survival (14.5    0.8 vs 11.3    0.8 years; P = 0.037). No correlation between endocrine or exocrine pancreatic function and @entity158 was found, whereas continuous @entity167 consumption was associated with poorer outcome regarding quality of life (P < 0.001) and @entity158 score (P < 0.001). CONCLUSIONS: PD and Frey procedure provide good and permanent @entity158 relief and improvement of the quality of life in long-term follow-up. In addition, a longer survival was found after the organ sparing resection. Together with better short-term results, the organ-sparing procedure seems to be favorable in treatment of chronic @entity788 .

title: Is the Whipple procedure harmful for long-term outcome in treatment of chronic XXXX ? 15-years follow-up comparing the outcome after pylorus-preserving pancreatoduodenectomy and Frey procedure in chronic @entity788 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory disease']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity1689 :: ('MESH:D050500', 'Disease') :: ['Chronic pancreatitis']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatitis']


abstract: Energy drink use has grown despite limited research to support efficacy or safety and amid concerns when combined with exercise. The purpose of this study was to assess the effects of 10 weeks of once-daily energy drink consumption or energy drink consumption with exercise on measures of body composition, @entity410 , strength, mood, and safety in previously sedentary males. Thirty-eight males were randomly assigned to energy drink + exercise (EX-A), energy drink (NEX-A), placebo + exercise (EX-B), or placebo (NEX-B). All @entity1 consumed 1 drink per day for 10 weeks; EX-A and EX-B participated in 10 weeks of resistance and endurance exercise. Testing was performed before (PRE) and after (POST) the 10-week intervention. No significant (p > 0.05) changes were observed for body composition, @entity410 , or strength in NEX-A; however, significantly greater decreases in fat mass and percentage body fat and increases in VO2peak were observed in EX-A versus EX-B. @entity1576 ( @entity1576 ), minute ventilation, VO2 at @entity1576 , and power output at @entity1576 improved significantly PRE to POST in EX-A but not in EX-B or nonexercising groups. Clinical markers for @entity65 , and immune function, as determined by PRE and POST blood work revealed no adverse effects in response to the energy drink. Mood was not affected by energy drink use. Absent energy restriction or other dietary controls, chronic ingestion of a once-daily low-calorie energy drink appears ineffective at improving body composition, @entity410 , or strength in sedentary males. However, when combined with exercise, preworkout energy drink consumption may significantly improve some physiological adaptations to combined aerobic and resistance training.

title: Low-calorie energy drink improves physiological response to exercise in previously sedentary XXXX : a placebo-controlled efficacy and safety study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['fitness', 'cardiorespiratory fitness']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['VT', 'Ventilatory threshold']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['hepatic, renal, cardiovascular']

answer: @entity1 :: (9606,Species) :: ['men']


abstract: Calcineurin inhibitors (CNIs) and @entity230 , the cornerstone of most immunosuppressive regimens in the past 20 years, have undesirable long-term side effects. This has led to the investigation of potential new strategies with @entity3446 (SRL) and @entity618 ( @entity2098 ). In the SPIESSER study, de novo CNI avoidance and early @entity134 withdrawal were evaluated in 145 renal recipients randomized to receive either SRL (n = 71) or @entity205 (CsA; n = 74). All patients received polyclonal anti-thymocyte globulin (ATG) for 5 days, @entity2098 , and @entity230 withdrawn at 6 months. At 12 months, @entity1 and graft survival, incidence of biopsy-proven acute rejection (BPAR), and rates of @entity134 withdrawal were not statistically different (97% vs 97%, 90% vs 93%, 14.3% vs 8.6%, and 82.8% vs 84.1%, respectively). In @entity1 who remained on treatment according to the protocol, estimated glomerular filtration rate (eGFR) was significantly higher with SRL (69 +/- 19 vs 60 +/- 14 mL/min; P < .01). In the CONCEPT study, early conversion from CsA to SRL was evaluated. One hundred ninety-two renal recipients were prospectively randomized at week 12 to switch from CsA to SRL (n = 95) or to continue CsA (n = 97). At 12 months, @entity1 survival rates (100% vs 100%) and graft survival rates (100% vs 98%), incidence of acute rejection (17% vs 8%), and rates of @entity134 withdrawal (72% vs 78%) were not significantly different between the SRL and the CsA groups. eGFR was significantly higher with SRL (68.9 vs 64.4 mL/min; P = .017; intent-to-treat analysis). In both studies, a significant improvement in renal function was observed at 12 months in @entity1 receiving a maintenance regimen with SRL and @entity2098 . In addition, @entity230 could be withdrawn in 70% of these @entity1 .

title: New approaches to de novo immunosuppression and XXXX elimination.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity134 :: (CHEBI:35341,Chemical) :: ['steroid']


abstract: Interaction of macrophages with bacteria is a stimulus for production of cytokines such as @entity688 and IL-12. IL-12 stimulates T cell and natural killer (NK) cell cytotoxicity and @entity379 ( @entity379 ) production. @entity688 opposes the T cell-stimulating action of IL-12, decreases the release of proinflammatory cytokines from macrophages, and stimulates B cells. We have studied the capacity of @entity1 intestinal isolates from the three @entity10263 species dominating on the @entity1 @entity344 , @entity1336 , @entity10263 and @entity6983 ssp. paracasei, to induce production of @entity688 and IL-12 from @entity1 blood mononuclear cells, or monocytes. Whole killed lactobacilli were potent stimulators of IL-12 over a wide range of bacterial concentrations. @entity6983 gave the highest levels of IL-12 (1.5 ng/ml in response to 5 x 106 bacteria/ml), roughly 10 times more than obtained by stimulation with @entity10263 or @entity1336 . @entity526 induced on average < 50 pg/ml of IL-12 regardless of the bacterial concentration used. The secretion of free @entity4666 subunit IL-12 followed the same pattern as the secretion of @entity12329 (bioactive IL-12) with regard to the efficiency of different bacteria as stimulators. @entity526 was the most efficient trigger of @entity688 production, inducing 0.5 ng/ml @entity688 after stimulation with 5 x 106 bacteria/ml. @entity10263 induced the highest levels of @entity688 among the lactobacilli (0.5 ng/ml) compared with 0.1 ng/ml evoked by @entity1336 or @entity6983 , but 10 times more bacteria were required for optimal stimulation than with @entity526 . When neutralizing anti- @entity688 antibodies were added to the cultures, the IL-12-inducing capacity of @entity10263 was increased markedly, while that of @entity526 remained low. The results show that mucosa-associated lactobacilli can be potent stimulators of IL-12, and thus potentially of cell-mediated immunity, if they pass over the gut epithelial barrier and interact with cells of the gut immune system.

title: Lactobacilli from @entity1 XXXX are strong stimulators of IL-12 production.

entities_list: @entity10263 :: ('47715', 'Species') :: ['Lactobacillus', 'Lactobacillus rhamnosus', 'L. rhamnosus']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal mucosa']

entities_list: @entity379 :: ('3458', 'Gene') :: ['IFN-gamma', 'interferon-gamma']

entities_list: @entity6983 :: ('1597', 'Species') :: ['Lactobacillus paracasei', 'L. paracasei']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity344 :: (MESH:D005767,Disease) :: ['gastrointestinal mucosa']


abstract: INTRODUCTION: @entity1067 ( @entity1067 ) is a common problem affecting middle-aged and elderly @entity1 . First-line medical therapy includes alpha 1blockers and @entity10831 inhibitors (5ARIs), such as @entity585 and @entity16503 . 5ARI use has been associated with adverse sexual outcomes, including @entity323 ( @entity323 ), @entity409 ( @entity409 ), and decreased libido. AIM: To clarify the association between @entity458 (AEs) and 5ARIs through review of literature concerning 5ARIs and to review the proposed mechanisms of these effects. METHODS: A comprehensive literature review, using MEDLINE and PUBMED search engines, was conducted for all publications concerning 5ARIs and sexual AEs. MAIN OUTCOME MEASURE: Sexual adverse effects, such as @entity323 , @entity409 , and decreased libido, were the measured outcomes of this literature review. RESULTS: Sexual AEs are reported in clinical trials at rates of 2.1% to 38%. The most common sexual AE is @entity323 , followed by @entity409 and decreased libido. These effects occur early in therapy and attenuate over time. A proposed mechanism for @entity250 involves decreased @entity842 synthase activity due to decreased @entity586 . CONCLUSIONS: The connection between 5ARIs and @entity250 is apparent upon review of the literature. Though theories have been proposed, little is known about the exact mechanisms behind 5ARI-related @entity250 . Since the connection between 5ARIs and sexual AEs is established in the literature, future research should be directed toward deciphering the pathophysiologic mechanisms. When more basic science knowledge is attained in this area, the focus can shift toward prevention and treatment.

title: XXXX inhibitors and @entity323 : the connection.

entities_list: @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction', 'ED']

entities_list: @entity586 :: ('MESH:D013196', 'Chemical') :: ['dihydrotestosterone']

entities_list: @entity585 :: ('MESH:D018120', 'Chemical') :: ['finasteride']

entities_list: @entity1067 :: ('MESH:D011470', 'Disease') :: ['Benign prostatic hyperplasia', 'BPH']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['EjD', 'ejaculatory dysfunction']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['sexual adverse effects']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity16503 :: ('MESH:C108373', 'Chemical') :: ['dutasteride']

entities_list: @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual dysfunction']

answer: @entity10831 :: (6715,Gene) :: ['5-alpha reductase']


abstract: This study examines the role of @entity10813 (1-13) and @entity34657 in the neuroendocrine regulation of anterior pituitary hormones in nonrestrained, adult male @entity2608 . The effects of these opioids on plasma concentrations of prolactin ( @entity34658 ), luteinizing hormone (LH), follicle-stimulating hormone (FSH), @entity7287 (TSH) and growth hormone (GH) were assessed. Intravenous administration of @entity10813 (1-13), 1-120 micrograms/kg, significantly increased plasma @entity34658 levels. Average maximal increases of 90-230% occurred within 5 min and levels remained significantly elevated for up to 120 min. @entity34658 response reached a plateau following the 30 micrograms/kg dose. @entity24566 had no observable effects on plasma concentrations of LH, FSH, TSH or GH at any dose level studied. Administration of @entity34657 produced significant dose-dependent increases in plasma @entity34658 concentrations. Dose levels of 1-120 micrograms/kg produced mean peak increases from 100 to 230%, 5-10 min postadministration. @entity34657 had no significant effect on plasma concentrations of LH, FSH, TSH or GH. The increases in plasma @entity34658 concentrations induced by @entity10813 were @entity1510 -reversible. These results indicate a selective effect of @entity10813 on the regulatory mechanisms of @entity34658 secretion over that of other anterior pituitary hormones.

title: Consequence of XXXX administration on anterior pituitary hormone concentrations in the adult male @entity2608 .

entities_list: @entity34657 :: ('MESH:C039666', 'Chemical') :: ['Dynorphin-A(1-10)-amide', 'dynorphin-A(1-10)-amide']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']

entities_list: @entity10813 :: ('MESH:D004399', 'Chemical') :: ['dynorphin-A']

entities_list: @entity7287 :: ('MESH:D013972', 'Chemical') :: ['thyrotropin']

entities_list: @entity2608 :: ('9544', 'Species') :: ['rhesus monkeys']

answer: @entity10813 :: (MESH:D004399,Chemical) :: ['dynorphin-A']


abstract: UNASSIGNED: Objectives To investigate the association between reproductive life stage, @entity158 complaint in a representative sample of @entity1 from S  o Paulo, Brazil. Methods A population-based survey was carried out with 574 @entity1 who were classified as being in the premenopausal or postmenopausal stage. They answered questions about @entity158 . Follicle stimulating hormone was collected to confirm menopausal condition along with clinical evaluation. Results In the whole sample, we found a prevalence of 56% for @entity158 perception and 20.2% for complaints of @entity4512 . Regarding the topography of @entity4512 , the distributions were similar among the premenopausal and postmenopausal groups. No significant association was found between reproductive life stage and @entity158 perception, as 58.1% of the premenopausal group and 52.0% of the postmenopausal group reported @entity158 . Similarly, there was no significant association between menopausal stage and @entity4512 , as 19.5% and 21.6% of the premenopausal and postmenopausal @entity1 , respectively, complained of @entity4512 . There was no significant association of postmenopausal stage (early or late) with @entity158 . The use of analgesics was significantly higher in postmenopausal compared to premenopausal @entity1 (p   <   0.001). Conclusion A high prevalence of @entity158 was found in @entity1 from the city of S  o Paulo. However, neither the presence of @entity4512 nor @entity158 perception were associated with the reproductive life stage, showing that both parameters was independent from the menopausal status in the studied @entity1 .

title: XXXX and the reproductive life stage in @entity1 : is there a relationship?

entities_list: @entity4512 :: ('MESH:D059352', 'Disease') :: ['musculoskeletal pain']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain perception and musculoskeletal pain', 'pain', 'pain perception or musculoskeletal pain']

answer: @entity4512 :: (MESH:D059352,Disease) :: ['Musculoskeletal pain']


abstract: BACKGROUND AND OBJECTIVE: Restenosis-rate after balloon-angioplasty of long segment tibial @entity455 is largely unknown. We investigated the restenosis-rates angiographically in @entity1 with @entity63 ( @entity63 ) due to extensive @entity75 . METHODS: Angioplasty for @entity75 exclusively >= 80 mm in length was performed using dedicated 80-120 mm long low-profile balloons. Follow-up included angiography at 3 months and clinical assessment at 3 and 15 months. RESULTS: Angioplasty was performed in 77 infrapopliteal arteries of 62 limbs of 58 @entity63 @entity1 with a Rutherford class 4 in 16 (25.8%) limbs and Rutherford class 5 in 46 limbs (74.2%). Average lesion length was 18.4 cm. Treated arteries were stenosed in 35.1% and occluded in 64.9%. After 3 months, a clinical improvement (marked reduction of @entity1066 ) was seen in 47 (75.8%) limbs, 14 (22.6%) limbs were clinically unchanged and 1 (1.6%) limb showed a clinical deterioration. Angiography at 3 months showed no significant restenosis in 24 of 77 (31.2%) treated arteries, a restenosis >= 50% in 24 (31.2%) arteries and a reocclusion in 29 of 77 (37.6%). At 15 months death rate was 10.5%. After repeat angioplasty in case of restenosis cumulative clinical results at 15 months were minor amputations in 8.1%, no major amputations resulting in a limb-salvage rate of 100% with no @entity1 requiring bypass surgery. CONCLUSIONS: Restenosis-rate after angioplasty of extensive @entity455 is high and occurs early after treatment. Despite this the clinical results are excellent, especially given the length of the arterial segments diseased.

title: Angiographic patency and clinical outcome after balloon-angioplasty for extensive XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['arterial disease', 'infrapopliteal arterial disease']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['critical limb ischemia', 'CLI']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['infrapopliteal lesions']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer-size or restpain']

answer: @entity455 :: (MESH:D014652,Disease) :: ['infrapopliteal arterial disease']


abstract: INTRODUCTION: @entity8 after @entity449 repair is an increasingly recognised problem. @entity544 ( @entity515 ) angiography has been used to limit the risk of contrast nephrotoxicity during endovascular procedures. This prospective study evaluates the performance of @entity515 angiography during EVAR. METHODS: Seventeen @entity1 undergoing EVAR over a 12 month period were included. All were males with a median age of 74 (range 62-86) years. The median preoperative @entity1011 was 105 (range 77-165) micromol/L. @entity515 angiography was used routinely in all @entity1 for graft positioning. Contrast was used for completion angiograms and whenever @entity515 did not satisfactorily demonstrate the anatomy. RESULTS: All @entity1 had successful deployment of stent graft. The median contrast usage was 59 (range 20-250)ml. @entity515 angiography successfully demonstrated the aortic and iliac bifurcation in all 17 cases and the renal artery anatomy in 9. 7 out of 17 @entity1 had both @entity515 and contrast completion angiography. @entity515 correlated with contrast angiography in 6 of the 7 @entity1 . There was no significant difference in pre and post-operative creatinine values (P >0.9; Wilcoxon test). CONCLUSION: @entity515 angiography is a useful adjunct to contrast during the performance of EVAR and helps reduce contrast load and the risk of contrast nephrotoxicity.

title: An evaluation of the use of @entity544 angiography in XXXX repair.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['Renal dysfunction']

entities_list: @entity449 :: ('MESH:D001014', 'Disease') :: ['endovascular aortic aneurysm']

entities_list: @entity544 :: ('MESH:D002245', 'Chemical') :: ['Carbon dioxide']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity449 :: (MESH:D001014,Disease) :: ['endovascular aortic aneurysm']


abstract: @entity35068 is a rare disease. We report an unusual case of this @entity5 arising in the ascending colon of a 32-year-old Japanese @entity1 who presented with @entity490 . An ulcerating mass in the colon was resected, along with enlarged mesenteric lymph nodes. Two years after surgery, the @entity5 recurred as @entity3799 and an intra-abdominal mass. Despite predonine and radiation therapy, the disease progressed, and the @entity1 died. The @entity5 cells had abundant fine granular or clear cytoplasm, and oval, lobulated, or indented nuclei. Numerous mature eosinophils were intermingled with the @entity5 cells. Immunohistologic studies on paraffin sections demonstrated that the majority of the @entity5 cells were strongly positive for CD45RB, @entity469 , and @entity13622 . They were unreactive, however, with a broad spectrum of antibodies against myelomonocytic and lymphocytic antigens. The mast cell nature of this rare type of @entity5 can be best identifiable by immunostains for @entity13622 .

title: XXXX with tissue eosinophilia arising in the ascending colon.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity35068 :: ('MESH:D012515', 'Disease') :: ['Mast cell sarcoma']

entities_list: @entity13622 :: ('25823', 'Gene') :: ['mast cell tryptase']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasm']

entities_list: @entity3799 :: ('MESH:D002575', 'Disease') :: ['left cervical lymphadenopathy']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

answer: @entity35068 :: (MESH:D012515,Disease) :: ['Mast cell sarcoma']


abstract: OBJECTIVE: Primarily to study morbidity and mortality in jejuno-ileal @entity1146 (JIA) and prognostic factors for outcome. Secondarily to look at the incidence of reintervention. METHODS: Retrospective review of 63 @entity1 diagnosed with JIA over a 30-year period (1975-2005). RESULTS: Sixty-three @entity1 (34 male) of mean gestational age 36 weeks and mean birth weight 2,858 g with JIA were studied. There were 14 type I, 14 type II, 16 type IIIA, 9 type IIIB, and 10 type IV @entity1146 . Thirty-three @entity1 (52%) had associated anomalies. Fifty-one @entity1 underwent resection and anastamosis, five @entity1 Bishop-Koop procedure, five ileostomies, and one strictureplasty. @entity384 severe enough to warrant surgical intervention was seen in seven @entity1 with the more severe variants of @entity1146 . Five tapering procedures, one @entity9728 and one STEP procedure were performed. Average hospital stay was 41 days (8-332 days). Fifty-six were alive at follow ups averaging 1.7 years (6 months to 11 years). Nine @entity1 needed reoperations for adhesions before the first year of life. There were seven deaths. Most @entity1 who died had associated anomalies (P = 0.017) or types IV/V @entity1146 (P = 0.007). CONCLUSION: Mild @entity1146 have an excellent prognosis and long-term survival. Severe @entity1146 are associated with longer PN support and secondary procedures for intestinal failure. @entity154 adversely affect outcomes in JIA.

title: Prognostic factors in jejuno-ileal XXXX .

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['Associated anomalies']

entities_list: @entity9728 :: ('MESH:C567398', 'Disease') :: ['Bianchi operation']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['Intestinal dilatation']

entities_list: @entity1146 :: ('MESH:D018633', 'Disease') :: ['atresias', 'atresia']

answer: @entity1146 :: (MESH:D018633,Disease) :: ['atresia']


abstract: OBJECTIVE: To determine the @entity3793 frequency in @entity1 with the cuticular drusen phenotype of @entity1020 ( @entity1020 ). METHODS: Fifty individuals were identified who met the criteria for the cuticular drusen phenotype using a standard threshold photograph. We genotyped DNA samples using a polymerase chain reaction-based restriction digest assay. Seven hundred individuals with typical @entity1020 and 252 controls were also genotyped. Fisher exact test was used to analyze the significance of allele frequency differences. RESULTS: The @entity3793 variant was present in 70% (frequency +/- SE, 0.70 +/- 0.05) of the cuticular cohort, 55% (frequency +/- SE, 0.55 +/- 0.01) of the more typical @entity1020 cases, and 34% (frequency +/- SE, 0.34 +/- 0.02) of controls. The association between the cuticular drusen phenotype and the @entity3793 allele was highly significant (P = .003; odds ratio, 2.0; 95% confidence interval, 1.21-3.07; vs @entity1020 cases P<.001; odds ratio 4.54; 95% confidence interval, 2.79-7.50; vs controls). Genotype distribution between the 3 groups was similarly significant (P<.001). CONCLUSION: The cuticular drusen phenotype is highly associated with the @entity9346 variant of the @entity4050 ( @entity4050 ) gene. The significantly higher @entity3793 allele frequency in this group compared with the typical @entity1020 cohort suggests that the complement cascade may play a greater role in the pathogenesis of the cuticular drusen subtype than in @entity1020 as a whole. CLINICAL RELEVANCE: The @entity32887 , @entity9346 allelic variant in the @entity4050 gene is associated with a 3-fold increased risk for @entity1020 . A high frequency of the @entity3793 allele has also been noted in @entity1 with membranoproliferative @entity631 .

title: XXXX polymorphism @entity9346 and cuticular Drusen.

entities_list: @entity9346 :: ('p|SUB|Y|402|H', 'ProteinMutation') :: ['p.Tyr402His', 'Tyr402His']

entities_list: @entity3793 :: ('CHEBI:27570', 'Chemical') :: ['histidine']

entities_list: @entity4050 :: ('3075', 'Gene') :: ['complement factor H', 'CFH']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis type II']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD', 'age-related macular degeneration']

answer: @entity4050 :: (3075,Gene) :: ['Complement factor H']


abstract: BACKGROUND: Hip abduction can cause @entity2530 ( @entity2530 ) of the femoral head in @entity1 . OBJECTIVE: To compare the US perfusion pattern of femoral head cartilage in neutral position with that in different degrees and duration of abduction, testing the @entity450 theory of post-abduction @entity63 . MATERIALS AND METHODS: In 20 neonates, the Doppler flow characteristics of the posterosuperior (PS) branch of the femoral head cartilage feeding vessels were evaluated in neutral and at 30 degrees, 45 degrees, and 60 degrees abduction. In three neonates the leg was held in 45-degree abduction and flow was assessed at 5, 10, and 15 min. RESULTS: Male/female ratio was 11/9 with a mean age of 1.86 +/- 0.7 weeks. The peak systolic velocities (PSV) declined in all three degrees of abduction. After 15 min of 45-degree abduction, the mean PSV declined and showed an absent or reversed diastolic component and undetectable venous return. No perfusion was detected at 60-degree abduction. CONCLUSION: Abduction-induced femoral @entity63 is biphasic and degree- and duration-dependent. In phase I there is arterial hypoperfusion and in phase II there is @entity450 . A new pathogeneses for femoral @entity63 is offered.

title: Biphasic threat to femoral head perfusion in abduction: arterial hypoperfusion and XXXX .

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['head ischemia', 'ischemia']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['venous congestion']

entities_list: @entity2530 :: ('MESH:D010020', 'Disease') :: ['AVN', 'avascular necrosis']

answer: @entity450 :: (MESH:D006940,Disease) :: ['venous congestion']


abstract: BACKGROUND AND PURPOSE: Wide-necked and @entity439 still remain a therapeutic challenge both surgically and endovascularly. The authors report their clinical experience and 5 year follow-up results using Neuroform stent, as an adjunct in the treatment of wide-necked and @entity439 . METHODS: One hundred and seven consecutive @entity1 with 110 wide-necked or fusiform @entity438 were treated with the Neuroform stent-assisted coiling. Both sequential technique and parallel technique were used. In all cases, embolization was completed by packing the @entity439 sac with a variety of commercially available coils. The technical feasibility of the procedure, procedure-related complications, angiographic results, clinical outcome and follow-up angiography were evaluated. RESULTS: In every case, the Neuroform stent system was delivered and deployed accurately, and @entity432 was achieved. Immediate angiography demonstrated complete @entity432 in 57.2%, neck remnant in 27.3% and incomplete @entity432 in 15.5%. Procedure-related morbidity was 5.6% and procedural-related mortality was 0.9%. Favorable clinical outcome (modified Rankin scale score: 0-2) was observed in 90.7% of the @entity1 (average follow-up time: 47.3 months). No rehemorrhage of treated @entity439 occurred. Angiography follow-up was obtained in 45.8% (49/107 @entity1 ; 51/110 @entity439 ; average follow-up time: 37.2 months). The overall recanalization rate was 13.7%. Comparison of @entity432 class immediately after treatment and at last follow-up showed that 86.3% of the 51 @entity439 had stable or improved class. Eight @entity439 (36.4%) that were not initially completely occluded converted to complete @entity432 on follow-up. No delayed coil or stent migration was found. One @entity1 with in-stent @entity850 and one with penetrating @entity432 occurred as delayed complications. CONCLUSION: In treating @entity438 , the Neuroform stent-assisted coiling is a secure and effective technique.

title: Neuroform stent-assisted coiling of XXXX : a 5 year single-center experience and follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'fusiform aneurysms', 'aneurysm']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['artery occlusion', 'occlusion']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['intracranial aneurysms', 'complex intracranial aneurysms']

answer: @entity438 :: (MESH:D002532,Disease) :: ['intracranial aneurysms']


abstract: BACKGROUND: There are no predictors known that can identify @entity1030 @entity1 who will respond to treatment with @entity16179 . METHOD: We investigated 30 @entity1 (median age 65 (range 44-83, 12 females) with mild to moderately severe @entity1030 . All @entity1 had post bronchodilator FEV1/forced vital capacity ratio of less than 70% and a reversibility of less than 12% and 200 ml from baseline. We wanted to determine if airway responsiveness ( @entity5874 ) to @entity112 and @entity2656 could predict who would respond to a 3-month course of @entity16179 . RESULTS: At baseline, all @entity1 had @entity5874 to @entity112 , but only 7 (23%) @entity1 to @entity2656 . After 3 months of treatment with @entity16179 , there was no significant change in spirometry or the quality of life when analysing all individuals together. However, FEV1% predicted improved from 67% (IQR12) to 79% (IQR16) in @entity2656 positive @entity1 ; whereas it was unchanged in the @entity2656 negative @entity1 . The difference in the mean change of FEV1% predicted between the two groups was 12 (IQR13.5) and this was highly significant (p=0.001). The improvement in quality of life (SGRQ 30 (IQR10.5) to 21 (IQR12; p=0.01) was only significant in the @entity1 positive to @entity2656 . CONCLUSION: We propose that @entity5874 to @entity2656 could predict @entity16179 -responsiveness in mild to moderately severe @entity1030 @entity1 .

title: Prediction of treatment-response to inhaled corticosteroids by XXXX -challenge test in @entity1030 . A proof of concept.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol']

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine']

answer: @entity2656 :: (MESH:D008353,Chemical) :: ['mannitol']


abstract: PURPOSE: To examine relationships between @entity5 , perfusion and metabolic microenvironment at the microregional level in three different @entity1 @entity957 (hSCC). MATERIALS AND METHODS: @entity19 bearing FaDu, UT- @entity31371 , and UT- @entity31372 hSCC were injected with @entity12184 @entity519 and Hoechst perfusion markers. Bioluminescence imaging was used to determine spatial distribution of @entity413 and @entity880 content in serial @entity5 sections. Metabolite levels were grouped in 10 concentration ranges. Images were co-registered and at each concentration range the proportion of area stained for @entity12184 and Hoechst was determined in 11-13 @entity5 per @entity5 line. RESULTS: The spatial distribution of metabolites in @entity12184 @entity519 and Hoechst perfused areas is characterised by pronounced heterogeneity. In all three @entity5 lines @entity413 concentration decreased with increasing @entity12184 @entity519 fraction and increased with increasing perfused area at the microregional level. A weak albeit significant positive correlation between @entity880 concentration and @entity12184 @entity519 fraction was found only in UT- @entity31372 . @entity880 concentration consistently decreased with increasing perfused area in all three @entity5 lines. CONCLUSIONS: Both @entity413 consumption and supply may contribute to the microregional @entity413 levels. Microregional @entity880 accumulation in @entity5 may be governed by clearance potential. The extent of microregional @entity519 cannot be predicted from the @entity880 concentration indicating that both parameters need to be measured independently.

title: Co-localisation of @entity519 and perfusion markers with parameters of XXXX metabolism in @entity1 @entity957 (hSCC) xenografts.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour hypoxia', 'tumours', 'tumour']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxic', 'hypoxia']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['Lactate', 'lactate']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity12184 :: ('MESH:C033815', 'Chemical') :: ['pimonidazole']

answer: @entity413 :: (MESH:D005947,Chemical) :: ['glucose']


abstract: BACKGROUND: Conventionally, a nebulized short-acting b-2 agonist like @entity3045 is often used as the reliever in acute exacerbations of @entity565 . However, recent worldwide respiratory outbreaks discourage routine use of nebulization. Previous studies have shown that combined @entity4184 / @entity6410 ( @entity28304  , AstraZeneca) is effective as both a maintenance and reliever anti- @entity748 medication. METHODS: We performed a randomized, open-label study from March until August 2011 to compare the bronchodilatory effects of @entity28304   vs. nebulized @entity3045 in acute exacerbation of mild to moderate @entity748 in an emergency department. Initial objective parameters measured include the @entity26 saturation, peak expiratory flow rate (PEFR) and respiratory rate. During clinical reassessment, subjective parameters [i.e., Visual Analog Scale (VAS) and 5-point Likert scale of breathlessness] and the second reading of the objective parameters were measured. For the 5-point Likert scale, the @entity1 were asked to describe their symptom relief as 1, much worse; 2, a little worse; 3, no change; 4, a little better; 5, much better. RESULTS: Out of the total of 32 @entity1 enrolled, 17 @entity1 (53%) were randomized to receive nebulized @entity3045 and 15 (47%) to receive @entity28304  . For both treatment arms, by using paired t- and Wilcoxon signed rank tests, it was shown that there were statistically significant improvements in @entity26 saturation, PEFR and respiratory rate within the individual treatment groups (pre- vs. post-treatment). Comparing the effects of @entity28304   vs. nebulized @entity3045 , the average improvement of @entity26 saturation was 1% in both treatment arms (p = 0.464), PEFR 78.67 l/min vs. 89.41 l/min, respectively (p = 0.507), and respiratory rate 2/min vs. 2/min (p = 0.890). For subjective evaluation, all @entity1 reported improvement in the VAS (average 2.45 cm vs. 2.20 cm), respectively (p = 0.765). All @entity1 in both treatment arms reported either "a little better" or "much better" on the 5-point Likert scale, with none reporting "no change" or getting worse. CONCLUSION: This study suggests that there is no statistical difference between using @entity28304   vs. nebulized @entity3045 as the reliever for the first 15 min post-intervention.

title: A randomized open-label trial on the use of @entity4184 / XXXX ( @entity28304  ) as an alternative reliever medication for mild to moderate @entity748 attacks.

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic', 'asthmatic attack']

entities_list: @entity3045 :: ('MESH:D000420', 'Chemical') :: ['salbutamol']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide']

entities_list: @entity6410 :: ('MESH:C012629', 'Chemical') :: ['formoterol']

entities_list: @entity28304 :: ('MESH:C452428', 'Chemical') :: ['Symbicort']

answer: @entity6410 :: (MESH:C012629,Chemical) :: ['formoterol']


abstract: BACKGROUND: Acute @entity401 is a rapidly progressive disease frequently leading to @entity1576 and mechanical ventilation. The prognosis is usually poor despite aggressive diagnostic and treatment efforts. METHODS: In this retrospective cohort survey, we enrolled @entity1 with hypoxemic @entity1576 who met predefined criteria of acute @entity16058 . @entity1 ' records, radiologic studies, and pathologic specimens were reviewed. All data were recorded in each @entity1 's study file and subsequently analyzed. RESULTS: Our cohort consisted of 5 @entity1 and 4 @entity1 with a mean age of 69.4 yr (55-80 yr). The chest radiograph in all @entity1 progressed to diffuse bilateral infiltrates over a 12-day course. All nine @entity1 had histological proof of @entity16 consistent with @entity401 , obtained by either transbronchial biopsy or open lung biopsy. All @entity1 required admission to the medical intensive care unit and mechanical ventilation. The mortality rate was 100%, and @entity1 died within 5-26 days of their admission to the unit. CONCLUSIONS: Acute @entity401 ( @entity3794 ) is an idiopathic, rapidly progressive and, at times, fatal form of @entity401 . A transbronchial biopsy is a logical first diagnostic step, to be followed by an open lung biopsy, if necessary. Response to @entity288 in our series was minimal. In @entity1 who fail to respond to conventional therapy and are otherwise appropriate candidates, lung transplantation may be considered as an additional alternative.

title: XXXX : clinical characteristics and diagnostic and therapeutic considerations.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient', 'men']

entities_list: @entity16058 :: ('MESH:D054988', 'Disease') :: ['idiopathic interstitial pneumonia']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['diffuse alveolar damage']

entities_list: @entity3794 :: ('MESH:D011658', 'Disease') :: ['Hamman-Rich syndrome']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure']

entities_list: @entity401 :: ('MESH:D017563', 'Disease') :: ['interstitial lung disease', 'acute interstitial pneumonia', 'interstitial pneumonia']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity401 :: (MESH:D017563,Disease) :: ['Acute interstitial pneumonia-Hamman-Rich syndrome']


abstract: The feasibility of combining UFT plus @entity4181 (LV) with alternating @entity2600 and @entity901 was investigated in the first-line treatment of @entity1 with advanced @entity14 . Twenty-five @entity1 , median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received @entity2600 180 mg m(-2) on day 1, @entity901 85-100 mg m(-2) on day 15 and UFT 200-300 mg m(-2) day(-1) with LV 90 mg day(-1), days 1-21 of a 28-day cycle. @entity1 were treated in cohorts of three. At the highest dose ( @entity2600 180 mg m(-2), @entity901 100 mg m(-2) and UFT 300 mg m(-2) day(-1)), three of four @entity1 experienced grade 3 @entity137 . @entity294 , @entity391 were dose-limiting. Three of nine @entity1 had grade 2 @entity137 at the maximum tolerated dose ( @entity2600 180 mg m(-2), @entity901 100 mg m(-2) and UFT 250 mg m(-2) day(-1)). There were no grade 3 @entity137 in the first month of therapy. The overall response rate was 71% in 21 evaluable @entity1 ; progression-free survival was 8.8 months. Alternating @entity2600 and @entity901 plus UFT is an effective and well-tolerated first-line treatment for @entity1 with advanced @entity14 . We recommend a dose of @entity2600 180 mg m(-2) on day 1, @entity901 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies.

title: Concurrent XXXX , @entity901 and UFT in first-line treatment of metastatic @entity14 : a phase I study.

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['Diarrhoea']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['lethargy and vomiting']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity2600 :: (MESH:C051890,Chemical) :: ['irinotecan']


abstract: OBJECTIVE: To determine the pattern of @entity17 ( @entity17 ) occurring during anti- @entity310 therapy. METHODS: Between June 2005 and April 2008, 1800 French rheumatologists and internists were contacted to report cases of @entity17 occurring in @entity1 treated with anti- @entity310 . RESULTS: After a median of 10.2 (1.5-39.9) months of treatment, 33 @entity1 developed @entity17 : 22 had CNS and 11 peripheral nervous system (PNS) involvement. Underlying diseases were @entity309 (n = 16), @entity5427 (n = 11), @entity11179 (n = 4), JIA (n = 1) and PM (n = 1). Anti- @entity310 was infliximab (n = 15), etanercept (n = 12) or adalimumab (n = 6). CNS involvement was encephalic lesions (n = 16), transverse @entity4685 (n = 8) or retrobulbar optic @entity5013 (n = 5). Cerebrospinal fluid (CSF) analysis in 16 @entity1 and MRI in 20 @entity1 were abnormal. All patients discontinued anti- @entity310 . Fifteen @entity1 required @entity230 . Twenty @entity1 initially improved. Five @entity1 developed @entity15 . PNS involvement was chronic (n = 9) or acute inflammatory demyelinating @entity305 (n = 2). CSF analysis revealed an increased protein level in nine @entity1 . Nerve conduction studies confirmed @entity336 in all these patients. Anti- @entity310 was discontinued in 10 @entity1 and 8 received i.v. immunoglobulins. Two @entity1 relapsed after introduction of another anti- @entity310 . Overall, a causal relationship between anti- @entity310 and @entity336 was considered as probable in 31 @entity1 and definite in 2 who had positive rechallenge. CONCLUSION: Causal relationship between anti- @entity310 and induction of @entity336 remains unclear, but in some cases the chronology of clinical events is suggestive. Nevertheless, @entity336 might persist despite treatment discontinuation, suggesting that anti- @entity310 could trigger the demyelinating process, which further evolves independently.

title: Pattern of XXXX occurring during anti- @entity310 therapy: a French national survey.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity17 :: ('MESH:D003711', 'Disease') :: ['demyelinating disorders', 'DDs']

entities_list: @entity305 :: ('MESH:D011115', 'Disease') :: ['polyneuropathy']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis']

answer: @entity17 :: (MESH:D003711,Disease) :: ['demyelination']


abstract: BACKGROUND: Brucellosis is one of the most frequent @entity166 in many regions of Iran. The purpose of this study was to evaluate different clinical, laboratory and therapeutic aspects of this disease. METHOD: This retrospective descriptive study was performed on @entity1 referred to two teaching hospitals in Tehran/Iran with @entity3377 diagnosis during the years 1998 - 2005. @entity1 ' signs and symptoms, laboratory findings and clinical responses were evaluated during the study period. RESULTS: More than half of the 415 @entity1 enrolled in this study were female. The duration of the symptoms was reported to be less than 2 months in 83.85% of the @entity1 prior to being examined in our centre. While sweating and @entity221 were the most common symptoms, peripheral @entity625 , @entity6592 and @entity381 were the most frequently reported signs. Rifampin plus @entity799 was the most common regimen administered in these cases (32%) and relapse was also more frequently seen in this group of @entity1 (13.8%), whilst @entity3403 and @entity799 led to the least number of relapses (2.5%). CONCLUSIONS: Brucellosis is known to have various manifestations, so it should be considered as one of the differential diagnoses of any @entity1 referred with different organs involvement accompanied with or without @entity221 . Relapse is one of the complications reported even following an appropriate treatment.

title: Clinical profile and management of XXXX in Tehran - Iran.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity6592 :: ('MESH:D058566', 'Disease') :: ['sacroiliitis']

entities_list: @entity3377 :: ('MESH:D002006', 'Disease') :: ['brucellosis']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity799 :: ('MESH:D015662', 'Chemical') :: ['cotrimoxazole']

entities_list: @entity3403 :: ('MESH:D004318', 'Chemical') :: ['doxycycline']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious diseases']

entities_list: @entity381 :: ('MESH:D013163', 'Disease') :: ['splenomegaly']

answer: @entity3377 :: (MESH:D002006,Disease) :: ['brucellosis']


abstract: Ukrain ( @entity22872 ) is a cytostatic and immunomodulating semisynthetic compound of @entity8504 -modified alkaloids of Chelidonium majus L. It has selective cytotoxicity against @entity5 cells without healthy cells damaging. Dosage range, methods of introduction and duration of administration of the drug vary. AIM: To carry out comparative investigation of effect of Ukrain on growth of different form of @entity8270 . METHODS: @entity8270 cells were transplanted intraperitoneally and subcutaneously between the scapulas. Ukrain was administered intraperitoneally for 6 days (0.25 mg per @entity19 of 20 g, it's 0.1 LD50). The effect of drug on @entity5 growth was evaluated by the indexes of @entity5 growth inhibition (in the case of solid form), total number of @entity5 cells in @entity843 , number of viable @entity5 cells (in the case of ascitic form) and average life span of experimental animals. Cell cycle distribution of @entity5 cells was determined by flow cytometry. The number of circulating phagocytes was determined by flow cytometry with use of @entity2823 -labelled @entity794 Cowan. RESULTS: Intraperitoneal Ukrain administration in @entity19 with ascite form of @entity8270 resulted in moderate @entity851 , but was accompanied by @entity32 and caused reduction of life span of experimental animals. In @entity19 bearing solid form of @entity8270 treatment with Ukrain led to significant @entity5 growth inhibition and slight increase of life span. In @entity19 bearing both of @entity5 variants treatment with drug caused restitution of the number of circulating phagocytes in peripheral blood, more expressed in @entity19 bearing ascite @entity5 variant. CONCLUSION: Thus, anticancer activity of the Ukrain is more expressed in the case of solid variant of @entity8270 . This effect is mediated by direct apoptotic action of drug on @entity8270 cells and positive immunomodulating effect on @entity5 -bearing organism.

title: Comparative investigation of the effect of ukrain on growth of @entity843 and solid forms of XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['acute local inflammation']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['tumor growth retardation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity8504 :: ('MESH:C035638', 'Chemical') :: ['thiophosphate']

entities_list: @entity8270 :: ('MESH:D002286', 'Disease') :: ["Ehrlich's carcinoma"]

answer: @entity8270 :: (MESH:D002286,Disease) :: ['Ehrlich's carcinoma']